{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:19:04Z","timestamp":1787548744737,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart failure with reduced ejection fraction (HFrEF) is a major cause of morbidity and mortality worldwide. Hyperkalemia is a common complication of chronic spironolactone therapy and may necessitate dose reduction or discontinuation, particularly in patients with impaired renal function. This study aimed to describe real-world spironolactone management patterns following the occurrence of hyperkalemia, evaluate guideline-directed medical therapy (GDMT) exposure (receipt of \u22653 drug classes), and explore factors associated with in-hospital mortality among hospitalized patients with HFrEF and hyperkalemia receiving chronic spironolactone therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center study included 146 adult HFrEF patients on spironolactone (May\u2013Dec 2023). Data on demographics, comorbidities, renal function, GDMT exposure, and outcomes were extracted from electronic records. Hyperkalemia was categorized as mild\u2013moderate (5.0\u20135.5 mmol\/L) or severe (&amp;gt;5.5 mmol\/L). Univariate logistic regression and multivariable Cox models identified predictors of in-hospital mortality. Kaplan\u2013Meier analysis compared survival by GDMT exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study cohort (\n                      <jats:italic>N<\/jats:italic>\n                      = 146) had a mean age of 58.34 \u00b1 12.89 years, with 74% having hypertension and 23% having chronic kidney disease. Among the included HFrEF patients receiving chronic spironolactone therapy and admitted with hyperkalemia, 87% had mild\u2013moderate and 13% had severe hyperkalemia at admission. Among the 136 patients with documented spironolactone management decisions, therapy was continued at the same dose in 13.2% of patients, dose reduced in 28.7%, and discontinued in 58.1%. Among patients with available follow-up potassium measurements, continuation of spironolactone at the same dose and dose reduction were associated with significant reductions in serum potassium levels over 72 h (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.04 and\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001, respectively), whereas discontinuation showed no significant change (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.18). In exploratory multivariable Cox regression analysis, increasing age (HR 1.05, 95% CI 1.01\u20131.10,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02) and chronic kidney disease (HR 2.10, 95% CI 1.05\u20134.20,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.03) were associated with higher in-hospital mortality. NYHA class III\u2013IV showed a higher hazard estimate but did not reach statistical significance (HR 1.55, 95% CI 0.95\u20132.80,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.08). In a separate exploratory adjusted analysis, receipt of \u22653 GDMT classes yielded a lower hazard estimate for in-hospital mortality (adjusted HR 0.62, 95% CI 0.21\u20131.80); however, this association did not reach statistical significance (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.30).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective cohort of hospitalized patients with HFrEF and hyperkalemia, spironolactone management most commonly involved dose reduction or discontinuation following hyperkalemia. Older age and chronic kidney disease were associated with higher in-hospital mortality in exploratory analyses, whereas receipt of \u22653 GDMT classes was associated with a lower adjusted hazard estimate that did not reach statistical significance. Overall, these findings are exploratory and hypothesis-generating and should be interpreted cautiously given the retrospective single-center design, the limited number of mortality events, and the potential for residual confounding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1870470","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:23:20Z","timestamp":1787545400000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of spironolactone management following hyperkalemia among hospitalized patients with heart failure and reduced ejection fraction: a retrospective single-center study"],"prefix":"10.3389","volume":"13","author":[{"given":"Abdullah Sameer","family":"Alshammari","sequence":"first","affiliation":[{"name":"Pharmaceutcial Practices Department, College of Pharmacy, Umm Al-qura University","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foud O.","family":"Bahamdain","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care Services, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma M.","family":"Alshahrani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, Shaqra University","place":["Dawadimi, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Kandasamy","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Khalid University","place":["Abha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ageeli","family":"Rabea Mussa Rabea","sequence":"additional","affiliation":[{"name":"Pharmaceutical Services Administration, King Faisal Hospital-Holy Capital Makkah","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wid","family":"Alyamani","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care Services, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Idris","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care Services, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Kamfar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care Services, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Almalki","sequence":"additional","affiliation":[{"name":"Nahdi Medical Company","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Baha University","place":["Al-Baha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Kanan","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Administration, Rafha General Hospital, Northern Border Health Cluster","place":["Rafha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisrin","family":"Bifari","sequence":"additional","affiliation":[{"name":"Pharmaceutcial Practices Department, College of Pharmacy, Umm Al-qura University","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaimaa","family":"Alsulami","sequence":"additional","affiliation":[{"name":"Pharmaceutcial Practices Department, College of Pharmacy, Umm Al-qura University","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmalik S.","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Pharmaceutcial Practices Department, College of Pharmacy, Umm Al-qura University","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Elkholy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care Services, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1136\/heartjnl-2020-318811","article-title":"Management of heart failure with reduced ejection fraction","volume":"108","author":"Haydock","year":"2022","journal-title":"Heart."},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers."},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/011573403X289572240206112303","article-title":"The interplay of comorbidities in chronic heart failure: challenges and solutions","volume":"20","author":"Agress","year":"2024","journal-title":"Curr Cardiol Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global Public Health Burden of Heart Failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-023-01887-4","article-title":"Guideline-directed medical therapy for the treatment of heart failure with reduced ejection fraction","volume":"83","author":"Patel","year":"2023","journal-title":"Drugs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5455\/medarh.2023.77.105-111","article-title":"The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure\u2013HFrEF","volume":"77","author":"Naser","year":"2023","journal-title":"Med Arch"},{"key":"B8","doi-asserted-by":"publisher","first-page":"102411","DOI":"10.1016\/j.cpcardiol.2024.102411","article-title":"Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS)","volume":"49","author":"Varghese","year":"2024","journal-title":"Curr Probl Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2174\/011573403X281390240219063817","article-title":"Aldosterone effect on cardiac structure and function","volume":"20","author":"Al-Hashedi","year":"2024","journal-title":"Curr Cardiol Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.15420\/cfr.2024.10","article-title":"Evidence for aldosterone antagonism in heart failure","volume":"10","author":"Sethi","year":"2024","journal-title":"Card Fail Rev."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the american college of cardiology solution set oversight committee","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/pharma1030009","article-title":"Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure","volume":"1","author":"Eworuke","year":"2022","journal-title":"Pharmacoepidemiology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e10032","DOI":"10.7759\/cureus.10032","article-title":"The utilization of spironolactone in heart failure patients at a tertiary hospital in Saudi Arabia","volume":"12","author":"Alotaibi","year":"2020","journal-title":"Cureus."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ehf2.15193","article-title":"Guideline-directed medical therapy rates in heart failure patients with reduced ejection fraction in a diverse cohort","volume":"12","author":"Berry","year":"2025","journal-title":"ESC Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2215\/CJN.13541021","article-title":"Hyperkalemia with mineralocorticoid receptor antagonist use in people with CKD: understanding and mitigating the risks","volume":"17","author":"Epstein","year":"2022","journal-title":"Clin J Am Soc Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/IJNRD.S326464","article-title":"Hyperkalemia in chronic kidney disease: links, risks and management","volume":"2022","author":"Sarnowski","year":"","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11739-023-03427-0","article-title":"Recommendations for the management of hyperkalemia in patients receiving renin\u2013angiotensin\u2013aldosterone system inhibitors","volume":"19","author":"De Nicola","year":"2024","journal-title":"Intern Emerg Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40119-022-00289-z","article-title":"Hyperkalemia: Prevalence, Predictors and Emerging Treatments","volume":"12","author":"Lariv\u00e9e","year":"2023","journal-title":"Cardiol Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1161\/CIRCULATIONAHA.123.067489","article-title":"Sex disparities in longitudinal use and intensification of guideline-directed medical therapy among patients with newly diagnosed heart failure with reduced ejection fraction","volume":"149","author":"Sumarsono","year":"2024","journal-title":"Circulation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.2646","article-title":"Sex differences among patients with transthyretin amyloid cardiomyopathy\u2013from diagnosis to prognosis","volume":"24","author":"Patel","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e009821","DOI":"10.1161\/CIRCOUTCOMES.122.009821","article-title":"Association between electrocardiographic age and cardiovascular events in community settings: the Framingham heart study circulation","volume":"16","author":"Brant","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B22","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J."},{"key":"B24","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/pds.3748","article-title":"Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor\/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort","volume":"24","author":"Abbas","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/jhm.13317","article-title":"Effectiveness and safety of early treatment with spironolactone for new-onset acute heart failure","volume":"19","author":"Huang","year":"2024","journal-title":"J Hosp Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1667236","DOI":"10.3389\/fcvm.2025.1667236","article-title":"Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Cardiovasc Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney","year":"2024","journal-title":"Kidney Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12882-022-02711-z","article-title":"Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1\u20133a chronic kidney disease: a pilot study","volume":"23","author":"Zhang","year":"2022","journal-title":"BMC Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1080\/14656566.2023.2245756","article-title":"Hyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy","volume":"24","author":"Sampani","year":"2023","journal-title":"Expert Opin Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e002022","DOI":"10.1136\/openhrt-2022-002022","article-title":"Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population","volume":"9","author":"Jonsson Holmdahl","year":"2022","journal-title":"Open Heart."},{"key":"B35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B36","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2459\/JCM.0000000000001827","article-title":"Hyperkalemia, guideline-directed medical therapy and outcomes in heart failure patients followed at a tertiary center","volume":"27","author":"Toma","year":"2026","journal-title":"J Cardiovasc Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/ajhp\/zxab215","article-title":"Romero A, Malone DC. Serum potassium changes due to concomitant ACEI\/ARB and spironolactone therapy: a systematic review and meta-analysis","volume":"78","author":"Villa-Zapata","year":"2021","journal-title":"Am J Health Syst Pharm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s43044-024-00436-y","article-title":"Predictors of mortality in heart failure patients with reduced or mildly reduced ejection fraction: The CASABLANCA HF Study","volume":"76","author":"Couissi","year":"2024","journal-title":"Egypt Heart J."},{"key":"B42","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"109731","DOI":"10.4330\/wjc.v17.i10.109731","article-title":"Sodium-glucose cotransporter 2 inhibitor in heart failure patients and their outcomes: A meta-analysis of randomized controlled trials","volume":"17","author":"Parsi","year":"2025","journal-title":"World J Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/phar.2091","article-title":"Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure","volume":"38","author":"Tran","year":"2018","journal-title":"Pharmacotherapy."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1002\/ehf2.14358","article-title":"Impact of adherence to guideline-directed therapy on risk of death in HF patients across an ejection fraction spectrum","volume":"10","author":"Chen","year":"2023","journal-title":"ESC Heart Fail."},{"key":"B47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jacc.2025.05.040","article-title":"Guideline-directed medical therapy and outcomes among patients with heart failure with improved ejection fraction","volume":"86","author":"Min","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ehjqcco\/qcaa032","article-title":"The independent reduction in mortality associated with guideline-directed medical therapy in patients with coronary artery disease and heart failure with reduced ejection fraction","volume":"7","author":"Wolfe","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1870470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:23:22Z","timestamp":1787545402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1870470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":48,"alternative-id":["10.3389\/fmed.2026.1870470"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1870470","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1870470"}}